| Mesenchymal stromal cells: clinical challenges and therapeutic opportunities J Galipeau, L Sensébé Cell stem cell 22 (6), 824-833, 2018 | 1421 | 2018 |
| Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages JS Wang, D Shum-Tim, J Galipeau, E Chedrawy, N Eliopoulos, RCJ Chiu The Journal of thoracic and cardiovascular surgery 120 (5), 999-1006, 2000 | 953 | 2000 |
| Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation M François, R Romieu-Mourez, M Li, J Galipeau Molecular therapy 20 (1), 187-195, 2012 | 782 | 2012 |
| Allogeneic marrow stromal cells are immune rejected by MHC class I–and class II–mismatched recipient mice N Eliopoulos, J Stagg, L Lejeune, S Pommey, J Galipeau Blood 106 (13), 4057-4065, 2005 | 667 | 2005 |
| Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature S Viswanathan, Y Shi, J Galipeau, M Krampera, K Leblanc, I Martin, ... Cytotherapy 21 (10), 1019-1024, 2019 | 579 | 2019 |
| The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a … J Galipeau Cytotherapy 15 (1), 2-8, 2013 | 498 | 2013 |
| Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats T van Haaften, R Byrne, S Bonnet, GY Rochefort, J Akabutu, ... American journal of respiratory and critical care medicine 180 (11), 1131-1142, 2009 | 492 | 2009 |
| International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials J Galipeau, M Krampera, J Barrett, F Dazzi, RJ Deans, J DeBruijn, ... Cytotherapy 18 (2), 151-159, 2016 | 487 | 2016 |
| Immunological characterization of multipotent mesenchymal stromal cells—The International Society for Cellular Therapy (ISCT) working proposal M Krampera, J Galipeau, Y Shi, K Tarte, L Sensebe Cytotherapy 15 (9), 1054-1061, 2013 | 466 | 2013 |
| Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner M Rafei, PM Campeau, A Aguilar-Mahecha, M Buchanan, P Williams, ... The Journal of Immunology 182 (10), 5994-6002, 2009 | 458 | 2009 |
| Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation B Annabi, YT Lee, S Turcotte, E Naud, RR Desrosiers, M Champagne, ... Stem cells 21 (3), 337-347, 2003 | 422 | 2003 |
| Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell J Stagg, S Pommey, N Eliopoulos, J Galipeau Blood 107 (6), 2570-2577, 2006 | 406 | 2006 |
| Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing M François, IB Copland, S Yuan, R Romieu-Mourez, EK Waller, ... Cytotherapy 14 (2), 147-152, 2012 | 381 | 2012 |
| Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model A Al-Khaldi, H Al-Sabti, J Galipeau, K Lachapelle The Annals of thoracic surgery 75 (1), 204-209, 2003 | 364 | 2003 |
| Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype R Romieu-Mourez, M François, MN Boivin, M Bouchentouf, DE Spaner, ... The Journal of Immunology 182 (12), 7963-7973, 2009 | 358 | 2009 |
| Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo A Al-Khaldi, N Eliopoulos, D Martineau, L Lejeune, K Lachapelle, ... Gene therapy 10 (8), 621-629, 2003 | 332 | 2003 |
| Mesenchymal stromal cell–derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction M Rafei, J Hsieh, S Fortier, MY Li, S Yuan, E Birman, K Forner, MN Boivin, ... Blood, The Journal of the American Society of Hematology 112 (13), 4991-4998, 2008 | 294 | 2008 |
| Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-γ, TGF-β, and cell density R Romieu-Mourez, M François, MN Boivin, J Stagg, J Galipeau The Journal of Immunology 179 (3), 1549-1558, 2007 | 293 | 2007 |
| IDO-independent suppression of T cell effector function by IFN-γ–licensed human mesenchymal stromal cells R Chinnadurai, IB Copland, SR Patel, J Galipeau The Journal of Immunology 192 (4), 1491-1501, 2014 | 286 | 2014 |
| Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular … H Qin, Q Shao, H Curtis, J Galipeau, DJ Belliveau, T Wang, ... Journal of Biological Chemistry 277 (32), 29132-29138, 2002 | 255 | 2002 |
Nicoletta Eliopoulos, M.Sc., Ph.D.Investigator, Lady Davis Institute, and Assistant Professor, Dept.of Surgery, McGill UniversityVerified email at mcgill.ca
